MGTX
MeiraGTx Holdings plc·Healthcare
8.97
3.961%(−0.37)
Market ClosedLast Updated: — ET
52W L: $4.5552W H: $9.88
MGTX NEWS
zacks.com
Mar 31
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
seekingalpha.com
Mar 27
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript
defenseworld.net
Mar 27
Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock
MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction that occurred on Tuesday, March 24th. The shares were sold at an average price of $7.41, for a total transaction of $459,420.00. Following the completion of the sale, the chief executive officer owned 1,449,695 shares
zacks.com
Mar 26
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.5 per share a year ago.
globenewswire.com
Mar 26
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to hold a program update and present long-term data for AAV2-hAQP1 program for the treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16 th , 2026 LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2025, and provided a corporate update. “We are delighted to have been awarded Breakthrough Designation for our AAV2-hAQP1 treatment for Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract,” said Alexandria Forbes, Ph.D.
defenseworld.net
Mar 16
MeiraGTx Holdings PLC (NASDAQ:MGTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of MeiraGTx Holdings PLC (NASDAQ: MGTX - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating
